by Five Rivers Rx | Jan 7, 2021 | DEA
In November 2020, the Drug Enforcement Administration (DEA) issued a Notice of Proposed Rulemaking (NPRM) proposing to revise its regulations relating to suspicious orders of controlled substances. The proposed rules will clarify requirements to process a suspicious...
by Five Rivers Rx | Sep 10, 2020 | DEA, Suspicious Order Monitoring
Public interest in the Opioid Epidemic has taken a back seat to this year’s events (COVID-19 pandemic, civil unrest, raging wildfires, elections), but new developments on suspicious order monitoring are expected to continue. Recent Developments In the last two...
by Five Rivers Rx | May 20, 2020 | DEA, Industry News, Suspicious Order Monitoring
Omnicare, a leading provider of closed-door pharmacy services, agreed to pay more than a $15 million civil penalty for allowing opioids and other controlled substances to be dispensed without a valid prescription. The fine zeroes in on a common issue amongst...
by Five Rivers Rx | Mar 12, 2020 | DEA, Suspicious Order Monitoring
The settlement between the California Board of Pharmacy and AmerisourceBergen demonstrates the importance of embracing Suspicious Order Monitoring as a systematic and procedural Background The California Board of Pharmacy settled its longstanding investigation of...
